Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain

Vertex's suzetrigine, an oral NaV1.8 pain signal inhibitor, has been accepted by the FDA for priority review to treat moderate-to-severe acute pain, with a PDUFA target action date of January 30, 2025.